Compare STTK & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STTK | FINW |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 242.1M |
| IPO Year | 2020 | 2021 |
| Metric | STTK | FINW |
|---|---|---|
| Price | $2.60 | $18.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $4.00 | ★ $21.67 |
| AVG Volume (30 Days) | ★ 171.3K | 11.1K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | $1,000,000.00 | ★ $80,198,000.00 |
| Revenue This Year | N/A | $72.14 |
| Revenue Next Year | N/A | $47.30 |
| P/E Ratio | ★ N/A | $17.05 |
| Revenue Growth | N/A | ★ 14.76 |
| 52 Week Low | $0.69 | $13.49 |
| 52 Week High | $2.71 | $22.49 |
| Indicator | STTK | FINW |
|---|---|---|
| Relative Strength Index (RSI) | 71.07 | 47.82 |
| Support Level | $1.93 | $17.77 |
| Resistance Level | $2.18 | $18.04 |
| Average True Range (ATR) | 0.18 | 0.56 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 97.78 | 23.53 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.